Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.

Lott, Dominik; Krause, Andreas; Dingemanse, Jasper; Lehr, Thorsten

Lott, Dominik; Krause, Andreas; Dingemanse, Jasper; Lehr, Thorsten.

Afiliação

Lott D; Saarland University, Department of Clinical Pharmacy, Saarbrücken, Germany; Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland. Electronic address: Dominik.Lott@uni-saarland.de.
Krause A; Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland.
Dingemanse J; Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland.
Lehr T; Saarland University, Department of Clinical Pharmacy, Saarbrücken, Germany.

Eur J Pharm Sci ; 89: 83-93, 2016 Jun 30.

Article em En | MEDLINE | ID: mdl-27108115

Assuntos

Rim/efeitos dos fármacos; Fígado/efeitos dos fármacos; Tiazóis/metabolismo; Tiazóis/farmacocinética; Adulto; Feminino; Humanos; Rim/metabolismo; Fígado/metabolismo; Masculino; Pessoa de Meia-Idade; Receptores de Lisoesfingolipídeo/metabolismo; Adulto Jovem

Palavras-chave

Hepatic impairment; Metabolite modeling; Population pharmacokinetics; Renal impairment; S1P(1) receptor modulator

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tiazóis / Rim / Fígado Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google